FRLN — Freeline Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Virgin Galactic, Boeing, Zscaler
U.S. STOCKS ON THE MOVE-Cruise operators, Freeline, GoodRx
Freeline climbs on $28 mln buyout deal by Syncona
Brief: Syncona Ltd To Acquire Freeline Therapeutics
Brief: Syncona To Acquire Freeline Therapeutics
Brief: Freeline Presents Positive New Data From Phase 1/2 GALILEO-1 Trial Of FLT201
U.S. STOCKS ON THE MOVE-Morgan Stanley, Procter & Gamble, Lululemon
Freeline rises on proposal for acquisition of all outstanding shares
Brief: Syncona Portfolio Ltd Submitted Non-Binding Proposal To Freeline Therapeutics Holdings
U.S. STOCKS ON THE MOVE-Fluor, Alphabet, Marathon Digital
U.S. STOCKS ON THE MOVE-Acuity Brands, Barrick Gold, Alphabet
U.S. STOCKS ON THE MOVE-Freeline, Tilray Brands, RPM International
Freeline soars on positive early-stage data for gene therapy in Gaucher disease
Brief: Freeline Announces First Patient Dosed With Its Novel Gene Therapy Candidate For Gaucher Disease
Brief: Freeline Therapeutics Holdings Reports First Quarter 2023 Financial Results
Brief: Freeline Granted ILAP Designation In U.K. By MHRA For FLT201, For Treatment Of Gaucher Disease
Brief: Freeline Announces Proposed ADS Ratio Change
Freeline's genetic disorder therapy development pause keeps Sangamo ahead - Truist
Freeline Therapeutics Holdings PLC reports results for the quarter ended in December - Earnings Summary